Incidence of second primary malignancies in women with different stages of breast cancer

doi:10.3389/fonc.2022.1047684

CNU IR > Offices > 456 > Item 310902800/34870

Please use this identifier to cite or link to this item: https://ir.cnu.edu.tw/handle/310902800/34870

Title:	Incidence of second primary malignancies in women with different stages of breast cancer
Authors:	Lin, Cheng-Yao Hsiao, Sheng-Yen Huang, Wen-Tsung Tsao, Chao-Jung Ho, Chung-Han Su, Shih-Bin Guo, How-Ran
Contributors:	Chi Mei Med Ctr, Dept Internal Med, Div Hematol Oncol Southern Taiwan Univ Sci & Technol, Dept Senior Welf & Serv Natl Cheng Kung Univ, Dept Environm & Occupat Hlth Chi Mei Med Ctr, Dept Med Res Chia Nan Univ Pharm & Sci, Dept Hosp & Hlth Care Adm Chi Mei Med Ctr, Dept Med Res Chi Mei Med Ctr, Dept Occupat Med Natl Cheng Kung Univ Hosp, Dept Occupat & Environm Med
Keywords:	second primary malignancies breast cancer chemotherapy radiotherapy cancer stage
Date:	2023
Issue Date:	2024-12-25 11:04:51 (UTC+8)
Publisher:	FRONTIERS MEDIA SA
Abstract:	Introduction: Breast cancer (BC) is the most common cancer in women worldwide. Because of the extended survival of patients with BC, the occurrence of second primary malignancies (SPMs) after BC is an important issue. Methods: We identified female patients with BC in the Breast Cancer Health Database of Taiwan, which includes four cancer registry datasets between 2002 and 2014 from Taiwan Cancer Registry. We compared the incidence of SPM between patients who received chemotherapy and/or radiotherapy with those who did not. Stratified analyses were performed according to the American Joint Committee on Cancer (AJCC) stage. The Cox regression model was used to identify the risk factors for SPM and evaluate their effects. Results: We enrolled 85,947 eligible patients with BC, and 2,656 (3.09%) patients developed SPM. The median duration of SPM was 2.70 (1.14-5.14) years. Radiotherapy was administered in 40,946 (47.64%) patients, and chemotherapy was administered in 52,120 (60.64%). The most common SPMs were digestive tract cancers (876, 31.89%). The risk factors for SPM included the AJCC stage, chemotherapy, radiotherapy, age, and underlying comorbidities. Neither chemotherapy nor radiotherapy was associated with an increased risk of SPM in any stage. In contrast, after adjusting for other risk factors, patients at stage III/IV who received both therapies had lower risks of SPM compared with those who did not (p = 0.047). Conclusion: The risk of SPM was different across BC stages. Neither chemotherapy nor radiotherapy was associated with an increased risk of SPM in women with BC.
Relation:	Frontiers in Oncology, v.12, Article 1047684
Appears in Collections:	[Offices] 456

Files in This Item:

File	Description	Size	Format
index.html		0Kb	HTML	3	View/Open

Loading...